Sharemaestro company-news research for Cullinan Oncology LLC (CGEM), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest CGEM news and sentiment
Cullinan Oncology LLC
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
16 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone68/100
→
Published 30-day score50/100
Latest source headline
Cullinan Therapeutics Doses First Patient in Phase 2 CLN-049 Study in Acute Myeloid Leukemia
MT Newswires · 08 Oct 2026 11:39
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
16 current stories are mapped specifically to CGEM.
The score uses 4 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.002.
Confidence is 15/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
15/100
Confidencethin evidence
100%/100
Company news16 company stories
94/100
Story agreement6/100 difference
News history
Daily score and story count over 30 days
15 Sep30 Sep14 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.002 after freshness weightingSource breadth80
4 independent publishersCompany relevance100
share tied directly to this companyFreshness13
recency-weighted evidenceAgreement94
how closely stories agreePublisher mix14
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202650USD 15.53+0.1%
02 Oct 202650USD 15.51+4.7%
25 Sep 202652USD 14.81-29.7%
18 Sep 202652USD 21.08+2.4%
11 Sep 202651USD 20.59-6.8%
04 Sep 202652USD 22.09+1.8%
28 Aug 202654USD 21.7+0.1%
21 Aug 202654USD 21.68+6.6%
Provisional evidence
News subjects
What is shaping the score
Market update509 stories · 56%
Analyst action524 stories · 25%
Earnings503 stories · 19%
Source mix
Where the evidence comes from
GuruFocus553 stories · 19%
Simply Wall St.503 stories · 19%
MT Newswires502 stories · 12%
MarketBeat502 stories · 12%
Investing News Network502 stories · 12%
Stocktwits431 stories · 6%
Insider Monkey571 stories · 6%
Recurring subjects
Subjects appearing most often
Life Sciences2Oncology1Earnings1Clinical Trials1Biotech1Autoimmune Disease1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
23 Jun50 neutral14 Oct 19:17
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 14 Oct 19:17 | 50 | +0 | 14/100 (-1) | 16 (-7) | Provisional |
| 08 Oct 23:59 | 50 | +0 | 15/100 (-1) | 23 (0) | Provisional |
| 05 Oct 23:59 | 50 | +0 | 16/100 (-1) | 23 (+1) | Provisional |
| 02 Oct 23:59 | 50 | +0 | 17/100 (-1) | 22 (+2) | Provisional |
| 01 Oct 23:59 | 50 | -1 | 18/100 (-3) | 20 (+1) | Provisional |
| 28 Sep 23:59 | 51 | -1 | 21/100 (-4) | 19 (+1) | Provisional |
| 26 Sep 23:59 | 52 | +0 | 25/100 (-3) | 18 (+1) | Provisional |
| 25 Sep 23:59 | 52 | +2 | 28/100 (+2) | 17 (+2) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 16 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Analyst action1 story
0.0%92.6%
Market update3 stories
4.0%3.5%
Each side uses the same scale: 0–92.6% of the retained directional evidence.
Where the influence comes from
92.6%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
Market updateNot used in direction
Cullinan Therapeutics Doses First Patient in Phase 2 CLN-049 Study in Acute Myeloid Leukemia
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 08 Oct 2026 11:39
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
—Unscored
Analyst actionNot used in direction
Cullinan Therapeutics (NASDAQ:CGEM) Stock Keeps "Buy" Rating at HC Wainwright
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 05 Oct 2026 07:00
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Analyst actionNot used in direction
CGEM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $35
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 02 Oct 2026 11:28
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Cullinan Starts FDA Submission for Zipalertinib-Chemotherapy Combo in Non-Small Cell Lung Cancer
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 02 Oct 2026 08:10
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 01 Oct 2026 23:30
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.8d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Cullinan Therapeutics Eyes December Data Catalyst for CLN-978 and CLN-049
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 28 Sep 2026 11:02
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Cullinan Therapeutics (CGEM) Expects Three T Cell Engager Data Readouts In Q4 2026
Cullinan Therapeutics (NasdaqGS:CGEM) plans to report clinical data updates from three T cell engager programs in Q4 2026. The update will include new results for autoimmune and oncology candidates Velinotamig, CLN-978, and CLN-049. Cullinan also anticipates starting a Phase 2 study of CL…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Cullinan Therapeutics (NasdaqGS:CGEM) plans to report clinical data updates from three T cell engager programs in Q4 2026. The update will include new results for autoimmune and oncology candidates Velinotamig, CLN-978, and CLN-049. Cullinan also anticipates starting a Phase 2 study of CLN-049 after discussions with the US Food and Drug Administration. The planned Q4 2026 readouts and CLN-049 Phase 2 launch sit alongside a broader picture our research has uncovered. Take a look at 3 warning signs (2 major) we have identified for Cullinan Therapeutics. This kind of T cell engager pipeline expos
- Published
- 26 Sep 2026 22:07
- News subject
- Earnings
- Why this score
- Negative financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Autoimmune DiseaseBiotechClinical TrialsOncology
69/100 tone
92.6% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 25 Sep 2026 13:01
- News subject
- Analyst action
- Why this score
- Analyst upgrade
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 47/100
- 30-day weight
- 92.6% of directional evidence · 19.3d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Analyst actionNot used in direction
CGEM Reiterated by BTIG -- Price Target Maintained at $40
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 25 Sep 2026 11:05
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.3d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Cullinan Therapeutics (Nasdaq: CGEM) has announced key fourth quarter 2026 milestones for its immunology and oncology T cell engager pipeline. The company plans to release multi-dose regimen data for CLN-978 in SLE, RA, and Sjögren's disease in December, and for Velinotamig in SLE at ACR …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Cullinan Therapeutics (Nasdaq: CGEM) has announced key fourth quarter 2026 milestones for its immunology and oncology T cell engager pipeline. The company plans to release multi-dose regimen data for CLN-978 in SLE, RA, and Sjögren's disease in December, and for Velinotamig in SLE at ACR Convergence 2026 in November. Additionally, updated data from the Phase 1 dose escalation study of CLN-049 in relapsed/refractory AML will be presented in December.
- Published
- 25 Sep 2026 02:50
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsLife Sciences
43/100 tone
4% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 24 Sep 2026 19:11
- News subject
- Market update
- Why this score
- Negative financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 30/100
- 30-day weight
- 4% of directional evidence · 20.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
—Unscored
Market updateNot used in direction
Cullinan Therapeutics Plans Q4 2026 Clinical Data Updates Across Three T Cell Engager Programs
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 24 Sep 2026 13:57
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Cullinan Therapeutics (CGEM) Could Be 50% Below Fair Value On Phase 3 Zipalertinib Data
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 24 Sep 2026 10:12
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
57/100 tone
3.2% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 24 Sep 2026 04:29
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 29/100
- 30-day weight
- 3.2% of directional evidence · 20.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Cullinan Therapeutics (Nasdaq: CGEM) announced that its CEO, Nadim Ahmed, and Chief Medical Officer, Jeffrey Jones, M.D., M.B.A., will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum. The event is scheduled for Thursday, September 24, 2026, at 1…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Cullinan Therapeutics (Nasdaq: CGEM) announced that its CEO, Nadim Ahmed, and Chief Medical Officer, Jeffrey Jones, M.D., M.B.A., will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum. The event is scheduled for Thursday, September 24, 2026, at 1:30 p.m. ET. A webcast will be available on the company's investor relations website.
- Published
- 21 Sep 2026 18:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.1d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Life Sciences
57/100 tone
0.3% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 17 Sep 2026 04:00
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 29/100
- 30-day weight
- 0.3% of directional evidence · 27.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Earlier company news
CGEM news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 65 older CGEM headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to CGEM, but the headline and available text are not mainly about Cullinan Oncology LLC. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of CGEM sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.